The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises Clearway on Agreements with PacifiCorp for Additional 210 MW of Battery Energy Storage in Utah
On October 9, 2026, Clearway Energy Group (Clearway) announced an additional 210 megawatts (MW) of battery energy storage to its Honeycomb Energy Center fleet in southern Utah, supported by long-term contracts with PacifiCorp. The new storage capacity will help balance supply and demand on Utah’s electrical grid. Wilson Sonsini Goodrich & Rosati advised Clearway on the transaction with PacifiCorp.
Client Highlights
Firm Advises Alector on $75 Million Underwritten Offering
On October 16, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock at an offering price of $2.05 per share, which represents a premium of approximately 7.3 percent over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000 before deducting the underwriting discounts and commissions and other estimated offering expenses. The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.
Client Highlights
Wilson Sonsini Advises Recursion on $200 Million Follow-On Offering
On October 16, 2026, Recursion Pharmaceuticals, a clinical-stage company using AI-enabled drug discovery and development, closed an underwritten public offering of 61,540,000 shares of its Class A common stock at a public offering price of $3.25 per share. The gross proceeds from the offering were approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Client Highlights
Wilson Sonsini Advises Iambic Therapeutics on $150 Million Initial Public Offering
Wilson Sonsini advised Iambic Therapeutics, a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, in connection with the company’s $150 million initial public offering (IPO). Iambic issued 9,375,000 shares of its common stock at a public offering price of $16 per share, with a 30-day option for the underwriters to purchase up to an additional 1,406,250 shares. Iambic’s common stock began trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol “IAM.”
Client Highlights
Wilson Sonsini Advises Amaero on IPO
On October 14, 2026, Amaero, a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing (AM) and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing (PM-HIP) manufacturing of large near-net-shape components, announced the pricing of its initial public offering of 4,705,883 shares of its common stock at a price of $4.25 per share. Amaero has also granted the underwriters a 30-day option to purchase up to an additional 705,882 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. Wilson Sonsini Goodrich & Rosati advised Amaero on the transaction.
Client Highlights
Wilson Sonsini Advises Meow on $31.6 Million Series B and Strategic Partnership
On October 15, 2026, Meow, a financial technology company, announced the completion of a $31.6 million Series B financing led by Stifel Financial with participation from Archetype. The financing is part of a broader strategic investment and partnership under which Stifel will offer a white-label version of Meow’s platform to its commercial banking clients, starting with venture and fund banking. Wilson Sonsini Goodrich & Rosati advised Meow on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.